MDRNA Announces Licensing Agreement with Roche
News Feb 16, 2009
MDRNA, Inc. announced that it has entered into an agreement with Roche in which Roche will obtain a non-exclusive license to a portion of MDRNA's technology platform for the development of RNAi-based therapeutics. Terms of the agreement were not disclosed.
"We are pleased to have Roche recognize the value of our drug discovery platform," stated J. Michael French, President and Chief Executive Officer of MDRNA.
"To have a portion of our platform in-licensed by Roche, a company with a significant effort in RNAi-based therapeutics, is a great testament to our intellectual property estate as well as the strong science being performed by our researchers. This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities. We look forward to working with Roche to capitalize on the platform capability we are licensing to them as part of this agreement."
RNAi-based Drug Shows Promise as Treatment for Chronic Hepatitis BNews
The novel therapy by Arrowhead Pharmaceuticals uses a mechanism called RNA interference to reduce the surface antigens created by chronic HBV infections.READ MORE
A More Effective Alternative to RNAi, CRISPR for Studying Protein FunctionNews
Trim-Away is a novel method enabling researchers to directly and rapidly destroy any protein in any kind of cell.READ MORE
New Blood Test Developed to Diagnose Ovarian CancerNews
Investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately.READ MORE